Hunan Hansen Pharmaceutical Co., Ltd. Class A
SSZSE:0024127.58
CNY
-0.05
(-0.66%)
ISIN
CNE100000PK2
Return %
Stock
S&P 500
1Y
13.30
13.14
3Y
16.98
80.78
5Y
34.16
67.74
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Zheng Qing Liu
- Full Time Employees
- 2,108
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- No. 2688, Yincheng Avenue Yiyang HU China 413000
- IPO Date
- May 25, 2010
- Website
- hansenzy.com
- Similar Companies
- Business
- Hunan Hansen Pharmaceutical Co., Ltd. is a China-based pharmaceutical company principally engaged in the research, development, manufacture, and sales of traditional Chinese medicine preparations, chemical medicines, and medical preparations. Its main products include Simotang oral liquid for abdominal distention and phlegmatic abdominalgia; Yushangling capsules for injuries from falls; Yinxingye capsules targeting stroke and chest distress; Suoquan capsules for kidney deficiency; as well as ginkgo biloba capsules, Tianma Xingnao capsules, Baibeiyi lung capsules, bitter ginseng capsules, glucamine injections, and various other tablets, capsules, granules, syrups, tinctures, pills, and injections. The company provides a broad range of dosage forms including injections, mixtures, tablets, capsules, granules, syrups, decoctions, tinctures, and pills. It serves both domestic Chinese markets and international markets from its headquarters in Yiyang, Hunan Province, China. Founded in 1998, the company operates as a high-tech enterprise recognized for its pharmaceutical manufacturing capabilities. In recent developments, Hunan Hansen Pharmaceutical renewed its drug production license with regulatory authorities in Hunan Province. The company has also obtained drug registration certificates for new chemical drugs, including Englitazone tablets used in type 2 diabetes treatment, reflecting expansion in its pharmaceutical product portfolio beyond traditional Chinese medicine. It continues to expand its market presence for its key products such as Simotang oral liquid, while planning to build a modern botanical medicine brand focusing on products like Tianma Xingnao capsules. The company achieved revenue growth and improved profitability in the first three quarters of 2024, with a year-on-year revenue increase and a net income rise of over 19%, demonstrating operational growth despite some fluctuations in earnings. Recent honors include recognition as a National High-tech Enterprise and various industry quality and brand awards. The company remains committed to developing new products that leverage traditional Chinese medicine advantages alongside suitable chemical medicines for evolving disease spectrums in China and abroad. Hunan Hansen Pharmaceutical targets industries including gastroenterology, orthopedics/traumatology, cardiovascular and cerebrovascular diseases, operating primarily in China with growing international reach. It employs over 1,500 staff and emphasizes R&D, production scale, and diversified pharmaceutical offerings. Major product categories include traditional Chinese medicinal oral liquids, capsules, injections, and chemical pharmaceutical products. The corporate strategy involves strengthening proprietary Chinese medicine brands and screening biomedicine industry projects for future growth.